Priya SA, Zelalem T, Thomas F, et al. SARS: Epidemiology, Clinica l Presentation, Management, ant Infection Control Measures[J]. Mayo Clin Proc, 2003,78:882-890.
[2]
MA LTU.PNA Vaccine: a review[J]. J Int Med,2003,253:402-410.
[3]
Qom E'de,zhu Q,Yu M,et al. A complete sequence and comparative analysis s train(BJ01)of the SARS-associated virus [J].Chin Scibull,2003,48(10): 941-94 8.
[4]
Krokhin O,Li Y,Andonov A,et al. Mass spectrometric characterization of p r oteins from the SARS virus:a preliminary report[J]. J Mol Cell Proteomics, 2 003,2(5):346-356.
[5]
Rota PA,Oberste MS,Monroe SS. Characterization of a novel coronavir us ass ociated with severe acute respiratory syndrome[J]. Science, 2003,300(5624):1 3 94-1399.
[6]
Krueger DK, Kelly SM, Lewicki DN. Variations in disparate regions o f the murine coronavirus spike protein impact the initiation of membrane fusion[J]. J Virol,2001,75(6):2792 -2802.
[7]
Sedegah M, Weiss W, Sacci JB Jr, et al. Improving protective immunity in d uced by DNA-based immunization: priming with antigen and GM-CSF encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus[J]. Immunol, 2 000,164(11):5905-5912.
[8]
Burger JA, Mendoza RB, Kipps TJ. Plasmids encoding granulocyte-macr ophage colony stimulating- factor and CD154 enhance the immune response to genetic vac cines[J].Vaccine, 2001,19(15-16):2181-2189.
[9]
Chow YH, Chiang BL, Lee YL, et al. Development of Th1 and Th2 population s and the nature of immune responses to hepatitis B virus DNA vaccines can be mod ulated by codelivery of various cytokine genes[J]. Immunol, 1998,160(3); 1320- 1329.
